Compare AEVA & CERT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AEVA | CERT |
|---|---|---|
| Founded | 2019 | 2008 |
| Country | United States | United States |
| Employees | 239 | N/A |
| Industry | Auto Parts:O.E.M. | Retail: Computer Software & Peripheral Equipment |
| Sector | Consumer Discretionary | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 860.9M |
| IPO Year | N/A | 2020 |
| Metric | AEVA | CERT |
|---|---|---|
| Price | $15.99 | $6.29 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 10 |
| Target Price | ★ $26.50 | $11.67 |
| AVG Volume (30 Days) | 1.1M | ★ 3.9M |
| Earning Date | 05-06-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 87.50 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $418,838,000.00 |
| Revenue This Year | $85.37 | $4.18 |
| Revenue Next Year | $132.72 | $5.39 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 8.75 |
| 52 Week Low | $6.86 | $5.19 |
| 52 Week High | $38.79 | $14.03 |
| Indicator | AEVA | CERT |
|---|---|---|
| Relative Strength Index (RSI) | 58.94 | 53.90 |
| Support Level | $15.78 | $6.04 |
| Resistance Level | $17.27 | $7.52 |
| Average True Range (ATR) | 1.15 | 0.30 |
| MACD | 0.25 | 0.10 |
| Stochastic Oscillator | 59.82 | 84.88 |
Aeva Technologies Inc through its Frequency Modulated Continuous Wave (FMCW) sensing technology, designs a 4D LiDAR-on-chip that, along with its proprietary software applications, has the potential to enable the adoption of LiDAR across broad applications from automated driving to consumer electronics, consumer health, industrial automation, and security application. The 4D LiDAR sensors are designed to detect both velocity and position, supporting perception and decision-making in automated systems. The company operates in North America, EMEA, and Asia. The company's revenue consists of sales of perception solutions or sensing systems and non-recurring engineering services. Geographically, it derives the majority of its revenue from North America.
Certara Inc accelerates medicines to patients using biosimulation software and technology to transform traditional drug discovery and development. It provides modeling and simulation, regulatory science, and assessment software and services to help clients reduce clinical trials, accelerate regulatory approval, and increase patient access to medicines. The company has its business presence in the Americas, which is also its key revenue-generating market, EMEA, and the Asia Pacific region.